

## **EDUCATION & MANAGEMENT DIVISION (EMD)**

**EMD Executive Committee (EMD-EC)**  
**Minutes of the strategic 2018 planning meeting**  
**Thu 18-Jan-2018 (9:00-17:00) and Fri 19-Jan-2018 (9:00-13:00)**  
**Milan, Italy (@IFCC Headquarters; 7<sup>th</sup> floor)**



<b>Members</b>	<b>Position</b>	<b>Term</b>	<b>Time of Office</b>	<b>Attendance</b>
<b>Leslie LAI – LL (MY)</b>	Chair	2nd	2018 01 – 2020 12	Present
<b>Elizabeth FRANK – EF (IN)</b>	Vice Chair, VLP Chair	1st	2017 01 – 2019 12	Skype, day2
<b>Nader RIFAI – NR (US)</b>	Member	1st	2018 01 – 2020 12	Present
<b>André ZIEGLER – AZ (CH)</b>	Corp. Rep., Secretary	1st	2018 01*– 2020 12	Present
<b>Ana Leticia MASELLI – AM (GT)</b>	Member	2nd	2017 01 – 2019 12	Apologies
<b>Silvia CARDINALE – SC (IT)</b>	IFCC Office			Present

\*As by new position (secretary) in Jan 2018

## 1. Welcome and introductions

LL welcomed the EMD-EC to the strategic planning meeting in Milan.

- A special welcome was given to NR who accepted the role as a new member to the EMD-EC replacing Paolo Fortina (PF) who left the EMD for the new IFCC/ Emerging Technologies Division (ETD).
- Paolo's prior function as the EMD-EC secretary was handed over to AZ so that AZ's functional time of office was reset from Jan-2017 to Jan-2018 (1<sup>st</sup> term).
- LL notified that 2 EC members (AM, EF) were unable to attend on site and had sent their apologies. EF joined the meeting by Skype on day 2.

As major focus for strategic planning

- LL reminded the members present of the EMD mission statement: "EMD will provide IFCC members and the healthcare community with education relevant to Clinical Chemistry and Laboratory Medicine, directed at scientific, management and clinical issues."
- Whilst educational material is being developed for both developed and emerging nations the focus of the EMD would be on emerging nations.
- LL emphasized the importance of the planning meeting: the EMD has grown in 2018 to 17 active functional units comprising 11 Committees (C), 4 Working Groups (WG), and 2 Special Projects (SP):

Overview on all functional EMD units (Status Jan-2018):

	<b>Committees</b>	<b>Chair</b>
9.2.4	Clinical Molecular Biology Curriculum (C-CMBC)	Evi Lianidou
9.2.5	Analytical Quality (C-AQ)	Annette Thomas
9.2.7	Evidence-based Laboratory Medicine (C-EBLM)	Annalise Zemlin
9.2.9	Clinical Laboratory Management (C-CLM)	Sedef Yenice
9.2.10	Internet and Distance Learning (C-IDL)	L Langman (Co-Chair)
9.2.11	Education in the Use of Biomarkers in Diabetes (C-EUBD)	Garry John
9.2.12	Cardiac Biomarkers (C-CB)	Fred Apple
9.2.13	Chronic Kidney Disease (C-CKD)	Flavio Alcantara
9.2.14	Point of Care Testing (C-POCT)	Rosy Tirimacco
9.2.15	Proficiency Testing (C-PT)	Alexander Haliassos
9.2.16	Value Proposition for Laboratory Medicine (C-VPLM)	Andrew St. John
<b>Working Groups</b>		
9.3.8	Laboratory Errors and Patient Safety (WG-LEPS)	Laura Sciacovelli
9.3.10	Harmonization of Interpretive Comments EQA (WG-ICQA)	Samuel Vasikaran
3.3.11	Personal Support (WG-PS)	Graham Beastall
<b>Special Projects</b>		
9.4.1	Visiting Lecturer Programme (VLP)	Elizabeth Frank
9.4.2	Flow Cytometry (WG-FC)	Ulrich Sack
9.4.3	Developing Quality Competence in Medical Labs(DQCML)	Egon Amann

- 4 Task Forces (TF) previously under the Executive Board umbrella became part of the EMD from Jan-2018, namely, Cardiac Biomarkers, Chronic Kidney Disease, Point of Care Testing, Proficiency Testing.
- 1 new committee has been established in 2018: C-VPLM.
- 1 working group of the EMD was terminated at the end of December 2017: Cancer Genomics (WG-CG)
- 1 new committee was formed (C-IDL) by merging C-DL, an EMD Committee with C-leL, a CPD committee with the appointment of a Co-Chair from EMD and a Co-Chair from CPD. In addition to the two Co-Chairs, there are two members from the EMD and two members from CPD.

Meeting preparation:

- SC provided a comprehensive pre-meeting package comprising agenda and relevant papers: 1) EB Durban Minutes. 2) EMD Report 2017. 3) VLP Report 2017. 4) VLP Applications 2018. 5) EMD Work Plan 2018. 6) EMD budget proposal. 7) Transformation of TFs into Cs.
- LL has sent a written invite to the 16 chairs of the functional units, so that a first proposal of their working plans was available during the meeting. The drafts were discussed in the meeting, compared to the strategic EMD focus and returned to the chairs with suggestions for alignment. Present minutes comprise the final aligned working plans.

Meeting minutes from Durban (21-23 Oct 2017) were approved by the EC, and no open actions were noted.

## **2. Notification of other business and finalization of the agenda**

No changes to the original agenda.

NR reminded those present of the importance to penetrate both developed and developing countries. He shared his experience with new adaptive e-learning platforms that could reach more people than learning in workshops. Examples were presented such as the AACC Learning Lab (based on the Danish Area 9 platform) including participants' self-assessments and feedback options (Link: [AACC.ORG/LEARNING LAB](http://AACC.ORG/LEARNING LAB)). Such platforms are likely to deliver more effective and cheaper ways of education – and in particular, qualitative measures of their progress, needs and interests. 130 lectures are part of the Clinical Chemistry Trainee Council which is free program and can be accessed on [www.traineecouncil.org](http://www.traineecouncil.org). The program is available in multiple languages.

## **3. Report from Executive Board**

### **3.1. "Summary minutes - EB Durban"**

Details are available online ([www.ifcc.org/executive-board-and-council/ebminutes/](http://www.ifcc.org/executive-board-and-council/ebminutes/)).

The most relevant items for the EMD being:

- Number of corporate members are declining – mainly for 2 reasons: 1) Routes of Education: Concerns whether education reaches the appropriate target group at congresses; 2) MedTech Europe code: taking effect in January 2018 (implication: direct sponsorship of speakers and delegates of educational activities are no longer be permitted; concerns about indirect sponsorship)
- Cash flow difficulties in 2018 as a result of a reduction of income (no major conference will be held in 2018) and increased expenditure (General Conference will be held).
- EB agreed that the WG-Cancer Genomics (WG-CG) should be terminated at the end of December 2017 as there had not been much activity and all the relevant guidelines had already been produced by other organisations.
- EB accepted the proposed nominations of new EMD members / chairs.

## **4. Review of EMD Committees (C) 9.2.n, Working Groups (WG) 9.3.n and Special Projects (SP) 9.4.n**

### **4.1. EMD Report 2017,**

- A shorter version of the EMD annual report (15 pages shortened to→ 7 pages) was prepared by LL and will be sent by the end of January 2018 to the EB for the annual IFCC report 2017.
- The "Present-Me" format, i.e., the tool to present online content on the e-Academy ([eacademy.ifcc.org](http://eacademy.ifcc.org)), was rather complicated to use and slowed down some of the activities. "Present-ME" is a proprietary format and subscribed by IFCC on an annual

basis. Because of recent owner changes, “Present-Me” will be replaced by Microsoft’s “Office Mix” which is also much easier to operate (mix.office.com). Silvia Colli-Lanzi and Paola Bramati gave a short demonstration of MS Office Mix.

- Committee on Distance Learning (C-DL), an EMD committee was merged on 1 January 2018 with Committee on Internet and e-Learning (C-IeL) from CPD (2 members and 1 co-chair from each of the two divisions) to form a new committee called Committee on Internet and Distance Learning (C-IDL). NR mentioned that some of the AACC material had been translated to other languages (Spanish, French, Portuguese, etc) and could be valuable for the C-IDL.
- WG-Cancer Genomics (WG-CG) was terminated on 31 December 2017. NR highlighted that “Circulating DNA (cancer or pre-natal)” and “Circulating tumor cells” are 2 of the top 5 attractive fields currently in emerging diagnostics (with related educational needs). It was concluded that the cellular part is covered by the liquid biopsy educational material of the Committee on Clinical Molecular Biology Curriculum (C-CMBC). The other aspect (DNA) should be ideally covered by a DNA expert that could take the vacant position on C-CMBC
- NR mentioned that educational activities can be enhanced by (i) bringing disciplines together (Medical + Lab; example: AACC, Area 9, and NEJM), (ii) producing regular highlight sessions (e.g podcasts; eNews), (iii) attractive format (multi-media; cheaper than historical printing), and (iv) granting translations by young scientists. For CME, learning level and objectives can be defined and/or adapted. Short demo of AACC’s “learning lab” was given by NR.
- Further educational gaps were discussed:
  - Clinical mass spectrometry (MS) seems to be currently under-represented: Ronda Greaves already provided 2 webinars “MS Harmonisation” (Sep 2013) and “Hormone profiles in preterm infants” (May 2015) as a good start. But given the rapid development of MS at current (science – not management), there might be needs of more MS webinars (e.g. genetic metabolics and pathogen identification). This could also attract more Corporate members such as Waters, Thermo, etc.
  - Educational needs in general:
    - how to get DIRECT feedback on IFCC members’ needs → next strategy meeting (e.g. survey)
    - define list of missing educational opportunities: e.g. top 10 important topics in functional groups (agreed in the group) and list what/how they can be addressed.
- Publications: The official IFCC journal is Clinica Chimica Acta, and the chairs should be encouraged to publish in it (helps to increase the impact factor). The IFCC electronic journal is eJIFCC.

#### **4.2. VLP Report 2017, and VLP Applications 2018**

- The topics for the VLP presentations are not decided by the EMD, but are proposed by the national societies applying for visiting lecturers. However, EMD updates the Speakers Bureau on an annual basis which lists the names of lecturers, their topics and language of instruction. (e.g. “ifcc-speaker-bureau-rev-8-sept-2017.pdf”)
- Any national member can apply, but each visiting lecturer must give a minimum of 2 lectures; meals and hotel accommodation and all local transportation must be paid by the national society; the return economy travel is supported by a generous grant from Abbott
- The members approved a VLP application from Tunisia.

### 4.3. EMD Work Plan 2018-2020 (aligned with the chairs)

It was concluded that each functional unit should prepare a minimum of 1 publication, 1 workshop or symposium and where appropriate up to six modules for the eAcademy per year

The following will be communicated to the chairs via footnote in the Strategic Plan Document:

[Currently being revised by CPD

- Symposia/workshops should be held at national, regional or international congresses.
- The length of presentations for the eAcademy ranges between 20 and 30 minutes. All topics should be decided and agreed with the Co-Chair of C-IDL, Dr Loralie Langman.]

The plans in detail:

#### 9.2.4 Clinical Molecular Biology Curriculum (C-CMBC)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Evi Lianidou	Chair	GR	2nd	2017 01 - 2019 12	
Ettore Capoluongo	Member	IT	1st	2017 01 - 2019 12	
Verena Haselmann	Member	DE	2nd	2017 01 - 2019 12	
N. N.	Member				VACANT
Andrea Ferreira-Gonzalez	Consultant	US			

Strategic Actions 2018-2020:

- To conduct one molecular biology workshop per year.
- To review and update the webpage.
- To contribute at least six presentations per year to the eAcademy.

#### 9.2.5 Analytical Quality (C-AQ)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Annette Thomas	Chair	UK	1st	2017 01 - 2019 12	
David Grenache	Member	US	2nd	2016 01 - 2018 12	
Alexander Haliassos	Member	GR	2nd	2017 01 - 2019 12	
Qing Meng	Member	CA	1st	2016 04 - 2018 12	
Lina Khorovskaya	Member	RU	1st	2017-01 - 2019 12	

Strategic Actions 2018-2020:

- To conduct at least one AQ workshop per year.
- To develop e-learning presentations of Principles of EQA and IQC.
- To develop other educational materials on AQ for IFCC website.
- To review and update webpage.
- To contribute at least six presentations per year to the eAcademy.

### 9.2.7 Evidence-Based Laboratory Medicine (C-EBLM)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Annalise Zemlin	Chair	ZA	1st	2018 01 - 2020 12	
Andrew Don-Wauchope	Member	CA	1st	2018 01 - 2020 12	
Julien Wils	Member	FR	2 <sup>nd</sup>	2018 01 - 2020 12	
Karina Rodriguez-Capote	Member	CA	2 <sup>nd</sup>	2017 01 - 2019 12	
Nuria Giménez Gomez	Member	ES	1 <sup>st</sup>	2017 01 - 2019 12	

Strategic Actions 2018-2020:

- To submit a proposal for at least one EBLM workshop per year and to make materials available on the IFCC website.
- To publish at least one publication every second year related to EBLM.
- To review and update webpage.
- To contribute at least five presentations per year to the eAcademy.

The chair expressed concerns that the C-EBLM will struggle to write one publication every year with all the committee members' other commitments.

### 9.2.9 Clinical Laboratory Management (C-CLM)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Sedef Yenice	Chair	TR	2 <sup>nd</sup>	2017 01 - 2019 12	
Matthias Orth	Member	DE	2 <sup>nd</sup>	2018 01 - 2020 12	
Ed Randell	Member	CA	1st	2016 04 - 2018 12	
Aye Aye Khine Wamono	Member	ZA	1st	2016 04 - 2018 12	
Praven Sharma	Member	IN	1st	2017 03 - 2019 12	

Strategic Actions 2018-2020:

- To conduct at least one Laboratory Management workshop per year.
- To produce support documents for Developing Quality Systems in the laboratory in collaboration with C-AQ by the end of 2018.
- To review and update webpage.
- To contribute at least six presentations per year to the eAcademy.

### 9.2.10 Internet and Distance Learning (C-IDL); EMD/CPD collaboration

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Loralie Langman	Co-Chair	US	1st	2018 01 - 2020 12	EMD
Eduardo Freggiaro	Co-Chair	AR	1st	2018 01 - 2020 12	CPD
Rojeet Shrestha	Member	NP	1st	2017 05 - 2019 12	
Janine Grant	Web Editor	AU	2 <sup>nd</sup>	2017 01 - 2019 12	
N. N.	Member				VACANT
N. N.	Member				VACANT
Ronda Greaves	Consultant	AU			
Janet Smith	Consultant	UK			

### 9.2.11 Education in the Use of Biomarkers in Diabetes (C-EUBD)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Garry John	Chair	UK	1st	2016 01 - 2018 12	
E. English	Member	UK	1st	2016 01 - 2018 12	
Rajiv Erasmus	Member	ZA	1st	2016 01 - 2018 12	
David Sacks	Member	US	1st	2016 01 - 2018 12	
Cas Weykamp	Member	NL	1st	2016 01 - 2018 12	

**All memberships (1st term) need to be renewed (or replaced) at end of this year.**

Strategic Actions 2018-2020:

- To conduct a minimum of one symposium/workshop per year
- To continue working with WHO and clinical associations, for example ADA, IDF and EASD.

### 9.2.12 Cardiac Biomarkers (C-CB)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Fred Apple	Chair	US	1st	2017 01 - 2019 12	
Peter Kavsak	Member	CA	1st	2017 01 - 2019 12	
Guillaume Lefevre	Member	FR	1st	2017 01 - 2019 12	
Kari Pulkki	Member	FI	1st	2017 01 - 2019 12	
Amy Saenger	Member	US	1st	2017 01 - 2019 12	
Richard Body	Member	UK	1st	2017 01 - 2019 12	
Su Ping Carolyn Lam	Member	SG	1st	2017 01 - 2019 12	
Torbjørn Omland	Member	NO	1st	2017 01 - 2019 12	
Paul Collinson	Consultant	UK			
Allan Jaffe	Consultant	US			
Jordi Ordoñez-Llanos	Consultant	ES			

- 10 Industry Corporate members participate on the C-CB meetings on a self-funded basis

Strategic Actions 2018-2020:

- ACTIVITY 1: Develop educational materials for a) high-sensitivity, contemporary and point of care cardiac troponin assays and b) natriuretic peptide assays used in clinical practice.
- ACTIVITY 2: Develop publishable laboratory medicine, interdisciplinary, expert opinion materials and present global workshops in collaboration with industry, clinical societies and other IFCC committees.
- ACTIVITY 3: Yearly update IFCC website of cardiac troponin assay and natriuretic peptide assay tables by both manufacturer claims and from peer-reviewed literature. Expand postings with additional interference tables for biotin and haemoglobin.
- ACTIVITY 4: Continuation of distribution of educational posters and mouse-pads, as well as pocket-cards, addressing high sensitivity cardiac troponin and natriuretic peptide assays at IFCC (laboratory medicine) and clinical society meetings.
- ACTIVITY 5: Develop a searchable 'App' that will be the educational tool for cardiac biomarker assays used in clinical practice by clinicians and laboratorians.
- ACTIVITY 6: Develop a study model to define a 'clinical scorecard' for high sensitivity cardiac troponin assays
- To conduct a minimum of one symposium/workshop per year.

- To contribute at least three presentations in 2018 to the eAcademy (for example, appropriate interpretive criteria).

### 9.2.13 Chronic Kidney Disease (C-CKD)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Flavio Alcantara	Chair	BR	1st	2016 02 - 2018 12	
Pradip Datta	Member	US	1st	2017 05 - 2019 12	
Anders Grubb	Member	SE	1st	2017 05 - 2019 12	
Michele Mussap	Member	IT	1st	2017 05 - 2019 12	
Vanja Radišić Biljak	Member	HR	1st	2017 05 - 2019 12	
Takashi Wada	Member	JP	1st	2017 05 - 2019 12	
John H. Eckfeldt	WASPaLM Nominee	US			

Strategic Actions 2018-2020:

- To conduct a minimum of one symposium/workshop per year.
- To conduct a survey on member countries regarding their CKD assay practices and EQA available information for creatinine and urine albumin assays.
- Publicize the available national guidelines on CKD from different countries.
- Provide a road map towards standardization of creatinine assays and support for countries in need with information on ongoing standardization projects.
- Become a bridge to the CKD efforts between IFCC and WASPaLM.
- Approach the interacting partners at KDIGO and nephrology societies.
- Become a candidate partner in areas where CKD testing plays an important role, such as in cardiovascular risk stratification in hypertension.
- To contribute at least two presentations in 2018 to the eAcademy (for example, impact of standardization on eGFR, and association of kidney disease with heart disease and hypertension).

### 9.2.14 Point of Care Testing (C-POCT)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Rosy Tirimacco	Chair	AU	extra	2018 01 - 2018 12	12-m extension to find new chair
Michel Vaubourdolle	Member	FR	2nd	2017 01 - 2019 12	
N.N.	Member				VACANT
N.N.	Member				VACANT
Markus Schwertfeger	CorpRep	CH	1st	2017 04 - 2019 12	Roche

Strategic Actions 2018-2020:

- To conduct one symposium/workshop per year.
- To contribute at least two presentations in 2018 to the eAcademy.



### 9.2.15 Proficiency Testing (C-PT)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Alexander Haliassos	Chair	GR	2nd	2017 01 - 2019 12	
Berna Aslan	Member	CA	2nd	2017 01 - 2019 12	
Anna Carobene	Member	IT	2nd	2017 01 - 2019 12	
Armand Perret-Liaudet	Member	FR	2nd	2017 01 - 2019 12	
Cas Weykamp	Member	NL	2nd	2017 01 - 2019 12	
Jian Dai	Corp.Rep.	US	2nd	2017 01 - 2019 12	Siemens
Michael Rottmann	Corp.Rep.	DE	2nd	2017 01 - 2019 12	Roche

Strategic Actions 2018-2020:

- To develop and implement the “A” analytes section of the online database (DB-PT) adding all the common analytes from the already registered EQA-PT providers.
- To initiate the development of e-documents on the use of the database - web applications (user manuals).
- To conduct one symposium/workshop per year.
- To discuss the possibility of implementing a novel PT scheme for the Stroke biomarkers in co-operation with a non-for-profit ISO 17043 accredited EQA organizer.

### 9.2.16 Value Proposition for Laboratory Medicine (C-VPLM)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Andrew St John	Chair	AU	1st	2018 01 - 2020 12	
N. N.	Member				VACANT
N. N.	Member				VACANT
N. N.	Member				VACANT

Strategic Actions 2018-2020:

- ACTIVITY 1: Using the application to high-sensitive troponin described in the recently published paper (St John et al 2017; <https://www.ncbi.nlm.nih.gov/pubmed/29223766>) apply the same value proposition (VP) concepts to tests highlighted in previous work by the informal Value Proposition Group such as NT-proBNP, calprotectin, D-Dimer and molecular based tests.
- ACTIVITY 2: Find sites and other collaborators (including all stakeholders as well as laboratory professionals) who can evaluate the value proposition concept using real world data; work has already commenced on finding sites to assess the VP concept for high-sensitive troponin.
- ACTIVITY 3: Assess the role of economic modelling in providing data to evaluate the value proposition concept. This will ideally be done in several different countries/healthcare systems so as to assess whether the VP concept has broad relevance.
- ACTIVITY 4: Develop education strategies and materials that can promote the concept of value to initially laboratory professionals but also to other relevant stakeholders in the clinical pathway as well as IVD industry members. Consider conducting this activity in collaboration with other value based groups including EFLM Test Evaluation Working Group (<https://www.eflm.eu/site/page/a/1158>) and Society to Improve Diagnostic Medicine (<https://www.improvediagnosis.org/page/AboutDiagnosticError>)

- **ACTIVITY 5:** Produce presentation material that demonstrate the Committees activities and progress and determine a forum in 2018 where these can be presented and discussed. Also submit similar material to the IFCC eAcademy.
- In relation to the above, the intention is to produce 1-2 further peer-reviewed publications in 2018 as well as submit applications for Symposia at national and international meetings in 2019.

### 9.3.8 Laboratory Errors and Patient Safety (WG-LEPS)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Laura Sciacovelli	Chair	IT	2nd+	2017 01 - 2019 12	
Mario Plebani	Past chair	IT			
Keila Furtado Veira	Member	BR			
Isabel Garcia del Pino Castro	Member	ES			
Agnes Ivanov	Member	EE			
Giuseppe Lippi	Member	IT			
Zorica Sumarac	Member	RS			
Jamie West	Member	UK			

based on EMD minutes from +)2012-12 and \*)2016-9 ([http://www.ifcc.org/ifcc-education-division/httpifccorghostinginsoftdkmedia4678932017\\_emd\\_june\\_minutes-confirmedpdf/](http://www.ifcc.org/ifcc-education-division/httpifccorghostinginsoftdkmedia4678932017_emd_june_minutes-confirmedpdf/))

Strategic Actions 2018-2020:

- To increase the number of laboratories that actively participate in the Quality Indicators program by at least 10% per year.
- To identify performance specifications for each Quality Indicator by the end of 2018 and to publish the findings in a peer-reviewed scientific journal.
- To develop and implement a plan for IFCC member societies, accreditation bodies and EQA/PT providers to disseminate the MQI project and promote increased laboratory participation.

### 9.3.10 Harmonization of Interpretive Comments External Quality Assurance (WG-ICQA)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Samuel Vasikaran	Chair	AU	2nd	2018 01 - 2020 12	
Mario Plebani	Past chair	IT			
Eric Kilpatrick	Member	UK			
Tony Badrick	Member	AU			
Ken Sikaris	Member	AU			
Jane French	Member	UK			
Jacqueline Osypiw	Member	UK			
Michael Metz	Member	AU			
Magdalena Turzyniecka	Member	ZA			

Strategic Actions 2018-2020:

- To support the development of locally led patient report comment EQA program in Africa.
- Work with ISO in order to include quality assessment of interpretive commenting in ISO 15189.
- Commence 1 project with EFLM WG-POST on Post-Analytical Phase (WG-POST) in 2018.

### 9.3.11 IFCC Working Group for Personal Support (WG-PS)

DIV/FUNCTIONAL UNIT	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Graham Beastall	Chair	UK	1st	2018 01 - 2020 12	

### 9.4.1 Abbott IFCC Visiting Lecturer Programme (VLP)

DIV/FUNCTIONAL UNIT	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Elizabeth Frank	Chair	IN	2nd	2016 01 – 2018 12	

Strategic Actions 2018-2020:

- To publicize VLP at least twice a year to member societies and to maximize utilization of funds provided by Abbott Diagnostics.
- To update Speakers' Bureau yearly

### 9.4.2 Working Group on Flow Cytometry (WG-FC)

NAME	POSITION	COUNTRY	TERM	TIME IN OFFICE	NOTES
Ulrich Sack	Chair	DE	extra	2017 01 - 2018 12	
Claude Lambert	Member	FR			
Andreas Spittler	Member	AU			
Katharina Psarra	Member	GR			
Cecilia Rodriguez	Member	AR			
Andrey M. Ivanov	Member	RU			
Matthias Schiemann	Member	DE			

Strategic Actions 2018-2020:

- To conduct one course per year in Europe and one course per year in South America and to explore conducting one course per year in Asia.
- To review and update webpage.

### 9.4.3 Developing Quality Competence in Medical Laboratories (DQCML)

NAME	POSITION	COUNTR Y	TERM	TIME IN OFFICE	NOTES
Egon Amann	Chair	DE	1st	2017 01 - 2019 12	
Janet Smith	Corresp. Memb.	UK			
Ronda Greaves	Corresp. Memb.	AU			
Victor Daka	Corresp. Memb.	ZM			

Strategic Actions 2018-2020:

- To conduct a minimum of two courses per year.

## 5. EMD input for EB strategic plan

How to grant broadest access of EMD activities. How to get broad feedback on educational needs. EMD suggestions for future WG plans, e.g.

- Strategic collaborations with clinical organizations
- Increase number of publications; also need to mention IFCC support
- Continuous update of individual websites
- CME programs
- Symposia: Importance to collaborate with / early announcement to local host

## 6. EMD strategic plan

Section 4.3 (see above) will be summarized as separate document (leaving out the tables of participants): EMD Strategic Plan 2018 to 2020.doc“:

## 7. EMD contributions to IFCC News

See last EMD-EC meeting minutes (Durban); NR will write articles for the next few issues of the eNews.

## 8. EMD sessions at IFCC congresses

See last EMD-EC meeting minutes (Durban); no further change.

## 9. Links with other Divisions

- Collaboration with SD (C-MD, WG-SIA, WG-HbA2 with C-EUBD) is ongoing
- C-IDL was established on 1<sup>st</sup> January 2018 and is a collaboration between CPD and EMD

## 10. Any other business

### 10.1. Budget

Request for 2018: 192 kCHF based on (Details for the 17 functional units and EC: see separate file Paper6)

### 10.2. 2017 EMD Functional units time in office

The following members have been approved by the EB for a second term:

- EMD-EC: Leslie LAI (MY), Chair
- C-EBLM: Julien WILS (FR); Member
- C-CLM: Matthias ORTH (DE); Member
- WG-ICQA: Samuel VASIKARAN (AU); Chair

The following have been approved by the EB as Chairs or Co-Chair for a first term from January 2018:

- C- EBLM: Annalise ZEMLIN (ZA)
- C-IDL: Loralie LANGMAN (USA)
- WG-PS: Graham BEASTALL (UK)

With Paolo Fortina (prior secretary to the EMD-EC meetings) having left in Jan-2018 for the new vice-chair of ETD, the secretary position on EMD has become vacant. The decision was taken to recommend to the EB that AZ should be appointed Secretary of the EMD for the next 3 years, from January 2018 till 31<sup>st</sup> December 2020.

### 10.3. Action items

Actions	Description	Responsible	Due Date	Status
1	Draft of strategic working plan: remove incomplete sentence in C-AQ starting with "It was"; correct date in C-DQCML from 208 to 2018	SC	Mar-2018	Done
2	Send invite and meeting details to new EMD-EC member NR (General Meeting Budapest 10-11 Nov 2018)	SC	Mar-2018	Done
3	Meeting EMD-EC with all EMD C/WG/SP chairs at the General Meeting in Budapest on 9-Nov: to inform/invite the chairs to have 15 min max and stringent timeline (with respect to total number of functional units)	SC	Mar-2018	
4	Remind chair of new C-VPLM to fill the vacant positions	SC	Mar-2018	Done
5	Re-Check email lists whether they contain all current collaboration partners of joined activities (co-chaired C-IDL; WG-HbA2/C-EUBD; see chapter 9)	SC	Mar-2018	
6	To send out links and e-brochure for AACCC's "learning lab" to EMD-EC ( <a href="http://aacc.org/education-and-career/learning-lab">aacc.org/education-and-career/learning-lab</a> ). Might serve as an example for adaptive format, increased reach and/or possibility of educational collaboration.	NR	Mar-2018	Done
7	Contact C-IDL and ask them whether interested in linking with webinars of AACCC available in many different languages (Spanish, French, Portuguese, etc) and creating a template to facilitate / harmonize webinars	NR	Mar-2018	Done
8	Contact C-CMBC and encourage to fill the vacant position with an expert of "circulating DNA"	NR	Mar-2018	
9	Educational needs for mass spectrometry: link with new ETD-division and Task Force on Paediatric Laboratory Medicine (TF-PLM) to encourage them providing additional webinars for e-Academy as shared activity (technique AND science content); potential candidate in case of vacant position: Dr. Hufnagel (proposal NR)	LL	Mar-2018	Done
10	Regulations and Footnote for IFCC publications (see 3 <sup>rd</sup> bullet point section 4.3): to clarify with EB and CPD, whether these regulations (2-6 external referees, EB decision) strictly apply. Compare with CLSI (rigorous review). If so, then integrate as 3 <sup>rd</sup> footnote to strategic plan.	LL	Mar-2018	
11	VLP: end of 2nd term for EF in Dec-2018; thus need to find a new Chair.	LL	Mar-2018	
12	Educational needs in general: sort out options to get DIRECT feedback on IFCC members' needs, and define list of missing educational opportunities	EMD-EC	Next strategy meeting	

### 11. Date and location of future IFCC meetings

See also <http://www.ifcc.org/ifcc-congresses-and-conferences/>

- a. General Conference (GC):
  - 2018: Budapest , Saturday and Sunday November 10 and 11, 2018; the EMD-EC will meet the 2 days before (8 and 9 Nov) and invites the chairs of the EMD functional units for each 15 min on 9-Nov
- b. EuroMedLab
  - 2019: Barcelona (Spain), 19 to 23-May
  - 2021: Munich (Germany), 16 to 21-May
- c. WorldLab
  - 2020: Seoul (Korea), 24 to 28-May

- d. Bergmeyer conference
  - None in 2018

**12. Date of next EMD meeting**

- Thursday and Friday November 8 and 9, 2018 prior to GC in Budapest;
- The chairs will be invited to meet with the EC on 9-Nov. Because of the many functional EMD units (N = 17), each chair can have a maximum of 15 min to meet with the EC; strict adherence to timeline/agenda thus will be important.

Minutes prepared by Andre Ziegler